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itive strains. Gram-positive bacteria were cultured 34% (n=25) and
fungal strains 3% (n=2).
Conclusions: The predominance of Gram-negative rods was caused
by ESBL positive and use of broad spectrum antimicrobial prophy-
laxis. The increased proportion of isolation Multi-Drug-Resistant
(MDR) bacteria to antimicrobial agents may be due to the frequent
use of these agents for prophylaxis of bacterial infections in liver
transplant patients. These (MDR) bacterial strains caused severe
UTI' s in patients after LT.
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Introduction: Fungal infection is a severe complication in patients
undergoing solid organ transplantations.
Objective: The objective of the study was to evaluate species dis-
tribution and antifungal susceptibilities of fungal isolates taken
from patients after solid organ transplantation (SOT).
Material and Methods: The study included samples of urine,
blood, systemic fluids and the swabs of the post-operative wounds,
haematomas, drains taken from patients after kidney, liver or si-
multaneous pancreas-kidney transplantation hospitalized in Insti-
tute of Transplantation Medicine, Medical University of Warsaw
and Department of General and Transplantation Surgery, Medical
University of Warsaw in 2005- 2007. All cultured specimens were
isolated by using Sabouraud medium with antibacterial protection
using chloramphenicol and gentamicin (bioMerieux, France or Ox-
oid, England). Yeast-like fungi was incubated on CHROMAgar Can-
dida Medium (Becton Dickinson R) and identified by using biochemi-
cal, automatic test ID32C (bioMerieux). Susceptibility of the strains
to the antifungal agents: amfotericin B, itraconazol, fluconazol,
voriconazol was tested using E-test (AB Biodisk) on RPMI agar plates
(BiolifeR).
Results: The positive cultures were obtained in 662 samples from
402 patients receiving immunosuppressive therapy. There were cul-
tured 267 isolates of Candida albicans, 223 Candida glabrata, 39
strains of C. parapsilosis, 37 C. krusei and 35 of Trichosporon
asahii, 20 Saccharomyces cerevisiae, 9 strains of Cryptococcus neo-
formans 5 C. lipolytica, 6 strains of C. lusitaniae and 4 of C. sake,
5 strain of C. quilliermondii, 3 C. rugosa and 9 moulds from As-
pergillus fumigatus species. From cultured strains 37.3% was natu-
rally fluconazole resistant and 0.5% amphotericin B resistant. The
acquired resistant to fluconazole was presented by 10 isolates, to
itraconazole 26, to voriconazole 2 and to amphotericin B by 3 iso-
lates.
Conclusions: The most numerable groups of isolated fungal species
in patients after SOT were C. albicans 40% of all isolates and
C. glabrata 33.7%. Moulds were cultured less often and they were
found only in 1.4% of positive cultures. More than one third of iso-
lated fungi were resistant to fluconazole.
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Background: The echinocandins and the new-generation azoles
have been a boon to physicians managing fungal infections in trans-
plant recipients. But Nature abhors a vacuum. In this report, we
describe 2 liver transplant recipients on the new broad-spectrum
anti-fungals who became colonized and infected with fungi resis-
tant to these new agents.
Methods: Retrospective chart review. MIC of Candida spp. to azole
anti-fungals measured by E-test method.
Results: Case 1, a 36-year-old man, received a right-lobe graft
for fulminant hepatic failure, likely drug-induced. The transplant
surgery was complicated by the need for a colostomy. While under
standard immunosuppression, he was given caspofungin (CAS) for
Candida lusitaniae in the bloodstream. Three weeks later blood
cultures grew Trichosporon asahii, which responded to voricona-
zole (VCZ). Case 2 was a 56-year-old man with chronic Hepatitis
B infection and hepatocellular carcinoma, who underwent living
donor liver transplant with a left-lobe graft. He received standard
immunosuppression. In the early post-transplant period, hypoden-
sities developed segment 3, suggestive of infarction. In the 3rd
post-transplant month, the fully-evolved infarcted areas were doc-
umented to be in communication with the biliary tree.
Repeated fevers led to the placement of a biliary drain. Bile aspi-
rated on the 79th post-transplant day (PTD) grew Candida albicans,
and the patient was given fluconazole (FCZ). A cholangiogram on
the 139th PTD led to bile aspiration that cultured out C. albicans
(FCZ MIC 1.5ug/ml) and C. krusei. A septic episode on the 150th
PTD led to the use of VCZ and broad-spectrum antibiotics. Bile as-
pirated on the 160th PTD grew C. glabrata that was resistant to
FCZ, VCZ, itraconazole and posaconazole.
Conclusions: Although CAS and VCZ have been a boon to physi-
cians managing fungal infections, their use can be associated with
the selection of fungi resistant to them. Care with the use of an-
tibiotics should extend to the anti-fungals as well.
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Objectives: To determine the causative agents of urinary tract in-
fections (UTIs) among renal transplant recipients and to compare
the antibiotic susceptibilities of Escherichia coli strains isolated
from complicated community-acquired UTIs and renal transplant
recipients.
Methods: We evaluated 108 episodes of 82 recipients (46 women)
with confirmed UTI who were transplanted during the period 1981
to December 2007 at our center. Medical records of the patients
were reviewed retrospectively. To compare the susceptibility rates
of E. coli, 226 isolates from non-transplant patients with compli-
cated community-acquired UTIs were also evaluated.
Results: The mean age of the patients was 35.9 years in the range
from 16 to 58 years. Sixty-three patients had single episodes. Sev-
enteen episodes (15.7%) occurred in the first month following the
transplantation, 32 (29.6%) in the period of the second month to
sixth month and 59 (54.6%) occurred six months after transplan-
tation. Sixty-six (61.1%) of the 108 isolates were Escherichia coli,
24 (22.2%) Klebsiella spp., 5 (4.6%) Enterococcus spp., 5 (4.6%)
Staphylococcus aureus, 3 (2.8%) Acinetobacter baumannii, 1 (0.9%)
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coagulase-negative staphylococcus, 1 (0.9%) Proteus mirabilis, 1
(0.9%) Pseudomonas aeruginosa, 1 (0.9%) Salmonella spp, 1 (0.9%)
Enterobacter aerogenes. The resistance rates of E. coli strains are
given in the table. Among the E. coli strains isolated transplant
recipients, ciprofloxacin resistance rates were 37.5% (3/8) in the
first month after transplantation, 71.4% (15/21) in the period of
the second month to sixth month, and 35.1% (13/37) 6 months af-
ter transplantation. The resistance rates of TMP-SMX in the same
time periods were 100% (8/8), 90.5% (19/21), and 73% (27/37), re-
spectively. See Table 1.
Table 1. The resistance rates of E. coli strains among renal recipients and
the complicated community-acquired UTIs isolates from non-transplant
patients
Antimicrobial agent Renal recipients, Community-acquired, P value
n=66 (%) n=226 (%)
Ampicillin 61 (92.4) 136 (60.2) <0.05
Amoxicillin/clavulanic acid 29 (43.9) 88 (38.9) 0.47
Cefazolin 28 (42.4) 74 (32.7) 0.15
Cefuroxime 21 (31.8) 51 (22.6) 0.12
Ceftriaxone 13 (19.7) 38 (16.8) 0.59
Gentamicin 24 (36.4) 33 (14.6) <0.05
Ciprofloxacin 31 (47.0) 85 (37.6) 0.17
TMP-SMX 54 (81.8) 95 (42.0) <0.05
Conclusion: E. coli was the most frequently isolated organism
from UTIs in renal transplant recipients. The rates of resistance
to TMP-SMX, ampicillin, gentamicin among E. coli isolated from re-
nal recipients were significantly higher than those in community-
acquired complicated UTIs. We have observed that the majority of
the UTIs occurred beyond the sixth month after transplantation,
probably due to the fact that prophylactic TMP-SMX treatment in
renal transplant recipients provides some protection against UTIs.
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Background: The importance role of C. pneumoniae latent infec-
tion in pathogenesis of atherosclerosis is been well known and clin-
ical efficacy of antibiotic therapy has been described. One of the
most important problems in the transplantation field is slow dete-
rioration of transplanted kidney function. Previous research by our
centre pointed to a significant role of C. pneumoniae infection in
the development of chronic renal allograft dysfunction. There are
trials that confirmed C. pneumoniae infection role in liver chronic
rejection and vasculopathy of the transplanted heart. Pathogenesis
of these changes were similar with atherosclerosis.
Objectives: The aim of the study was to evaluate the C. pneu-
moniae presence prior to and after kidney transplantation and to
determine the role of spiramycin therapy in patients after kidney
transplantation.
Material and Methods: The study group consisted of 50 patients
(25 pairs) who received kidney transplants from cadaveric donors.
One of the two kidneys from one donor was transplanted to a pa-
tient randomised to spiramycin (dose of 2x3milion U/day orally for
3 months) (group S) and the other was transplanted to a patient as-
signed as control (group C). Markers of infection were assessed on
day 1 post transplantation and 3 months later (average=94 days).
All (n=50) patients were examined for bacterial DNA presence in
peripheral blood leukocytes using real-time PCR and titers of serum
anti C.pneumoniae IgG and IgA antibodies using microimmunofluo-
rescence (MIF). C. pneumoniae infection was diagnosed as C. pneu-
moniae DNA presence in peripheral blood leukocytes or positive
antibodies titres in both classes IgA (titer>1:16) and IgG (titer
>1:64).
Results: C. pneumoniae infection was initially diagnosed in 14 pa-
tients from group S and in 8 patients from group C (p=ns) after 3
months in 12 and 9 patients respectively (p=ns). Conversion from
positive to negative C. pneumoniae status occurred in 7 patients
from group S and one patient from group C (p=0.04). Conversion
from negative to positive C. pneumoniae status occurred in 5 pa-
tients from group S and 2 patients from group C (p=ns). Negative
C. pneumoniae status during research occurred in 6 patients from
group S and in 15 patients from group C (p= 0.02).
Conclusions: The results suggest a possible role for spiramycin
treatment of in C. pneumoniae infection in kidney allograft re-
cipients. Spiramycin is safe and has no significant interactions with
immunosuppresion treatment in kidney allograft recipients.
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Background: End-stage Chronic Chagas heart disease (ChD) caused
by T. cruzi involves dilated cardiomyopathy, complex arrhythmias,
heart failure and sudden death. Heart transplantation (HT) is a
valid treatment for ChD but reactivation of T. cruzi (RA) is the
main complication of concomitant immunosupression. Natural T.
cruzi populations display different tissue tropisms, growth rates
and drug susceptibility. Their genetic polymorphism supports dis-
tinction of two major lineages: T. cruzi I and II. They have been
identified from cultured stocks, underestimating diversity and pre-
cluding direct association studies of the parasite role with patho-
genesis.
Objectives: To follow-up T. cruzi infection and genotype popula-
tions associated to heart tropism and RA directly in clinical samples
from ChD undergoing HT, using molecular methods.
Methods: 9 ChD patients with a mean follow-up of 907 days
(37–2279 d); routine parasitologic tests and PCR of minicircle DNA
(kDNA) in blood, cardiac explants, endomyocardial biopsies of the
allograft heart and skin lesions. Lineage identification was done
by genomic PCR (Lg-PCR) and intra-lineage typing by RFLP-PCR of
kDNA.
Results: Sections from 7/8 heart explants of ChD were kDNA-PCR+
and 6/7 Lg-PCR+ (2 Tc I, 3 Tc II and 1 both). RFLP-PCR profiles were
polymorphic in different patient' s hearts and also among sections
of a same explant. Between 1-3 and 1-6 weeks after HT, kDNA-PCR
and Lg-PCR turned into positive in the 9 patients, showing recrude-
scence of infection leading in 6 to patent parasitemia concomitant
with RA within a mean period of 71.6 days. 4/9 ChD had TcI and
5/9 Tc II in blood. Lg-PCR was positive earlier in Tc II than in Tc I
infections. 5/6 RA patients developed lower limbs skin lesions and
1 chagasic myocarditis; in 5 patients identical lineages and RFLP-
